A test commonly used in breast cancer has been found to also identify which patients with aggressive prostate cancer will benefit from hormonal therapy, according to a study led by scientists at UC San Francisco and the University ...
May 17, 2017
0
3
Psilocybin treatment in a community setting appears safe and effective for patients with cancer and depression, according to a research letter published online April 13 in JAMA Oncology.
Apr 17, 2023
0
29
(HealthDay)—The C-509T allele in the promoter region of transforming growth factor β (TGFB1) is associated with radiation-induced breast fibrosis risk among patients with early-stage breast cancer, according to study published ...
Aug 2, 2018
0
0
Patients with very advanced solid tumors saw no significant improvement in overall survival after receiving systemic therapy, according to a study published in JAMA Oncology by researchers at The University of Texas MD Anderson ...
May 16, 2024
0
14
A new study shows that a test physicians commonly used to guide chemotherapy treatment for post-breast cancer surgery patients may also help them decide whether radiation therapy may be of benefit.
Jan 9, 2020
0
4
Prostate-specific antigen (PSA) screening is associated with decreased risk of prostate cancer-specific mortality (PCSM) among both Black and White men, according to a study published online Aug. 4 in JAMA Oncology.
Aug 10, 2022
0
2
In one of the largest clinical studies to ever examine the impact of using a blood test to detect treatable mutations in non-small cell lung cancer (NSCLC), researchers from the Abramson Cancer Center of the University of ...
Oct 11, 2018
0
1
(HealthDay)—For patients with advanced squamous non-small cell lung cancer (sq- NSCLC), adding tislelizumab in combination with chemotherapy is associated with improved progression-free survival (PFS), according to a study ...
Apr 5, 2021
0
2
Back-to-back discoveries from Cleveland Clinic demonstrate for the first time how a testosterone-related genetic abnormality can help predict individual patient responses to specific prostate cancer therapies.
Oct 12, 2017
0
2
(HealthDay)—Metastatic castration-resistant prostate cancer (mCRPC) has heterogeneity in positron emission tomography (PET)/computed tomography (CT) imaging phenotype, which has clinical relevance, according to a study ...
Nov 16, 2017
0
10
